hct
recipi
surveil
studi
pediatr
adult
hct
recipi
first
year
transplant
common
virus
detect
hrv
hcov
follow
piv
adenoviru
rsv
influenza
hmpv
human
bocaviru
separ
multicent
retrospect
studi
pediatr
hct
recipi
patient
least
one
respiratori
viru
detect
pcr
first
year
hct
younger
age
associ
viral
detect
univari
analysi
steroid
exposur
neutropenia
lymphopenia
commonli
present
week
respiratori
viral
onset
larg
multicent
retrospect
studi
pediatr
sot
recipi
highest
rate
inpati
respiratori
viru
infect
occur
intestineabdomin
multiviscer
transplant
recipi
follow
thorac
heartlung
liver
kidney
transplant
hrv
common
detect
viru
respiratori
viru
event
follow
rsv
piv
hmpv
influenza
lymphopenia
present
patient
respiratori
viru
detect
although
evalu
risk
factor
acquisit
oncolog
patient
larg
cohort
pediatr
cancer
patient
fever
neutropenia
least
one
respiratori
viru
detect
subject
common
respiratori
virus
detect
hrv
rsv
piv
influenza
adenoviru
hmpv
healthi
individu
respiratori
viral
infect
associ
selflimit
upper
respiratori
tract
symptom
notabl
except
includ
stronger
associ
rsv
bronchiol
young
infant
piv
laryngotracheobronch
hrv
reactiv
airway
diseas
exacerb
immunocompromis
patient
respiratori
viral
infect
associ
prolong
shed
lower
respiratori
tract
diseas
need
supplement
oxygen
late
airflow
obstruct
even
death
prolong
viral
shed
associ
persist
respiratori
symptom
asymptomat
durat
week
mean
persist
shed
piv
asymptomat
immunocompromis
patient
mani
month
note
use
sensit
molecular
detect
method
prolong
shed
describ
hmpv
hcov
hrv
impair
tcell
function
appear
commonli
associ
children
prolong
shed
addit
risk
factor
hct
recipi
includ
initi
high
viral
load
use
steroid
myeloabl
condit
initi
clinic
symptom
relat
rsv
infect
immunocompromis
host
similar
immunocompet
person
upper
respiratori
tract
infect
may
progress
lower
respiratori
tract
diseas
likelihood
progress
probabl
relat
immun
statu
week
lower
respiratori
tract
involv
may
becom
evid
increas
respiratori
distress
worsen
hypoxia
potenti
need
assist
ventil
children
adult
acquir
rsv
hmpv
shortli
chemotherapi
malign
may
also
sever
lifethreaten
diseas
recoveri
assist
ventil
rsv
hmpv
pneumonia
occur
remain
uncommon
despit
advanc
support
care
associ
respiratori
failur
sever
immunocompromis
patient
may
result
multiorgan
system
failur
high
mortal
rate
patient
requir
mechan
ventil
sever
fatal
infect
attribut
hmpv
report
cancer
patient
hmpv
rel
common
caus
acut
respiratori
infect
children
adult
malign
hct
recipi
organ
transplant
recipi
risk
factor
sever
hmpv
infect
includ
lymphopenia
quantit
bronchoalveolar
lavag
bal
viral
load
associ
mechan
ventil
death
rsv
piv
hmpv
adult
patient
hct
howev
detect
respiratori
viru
rna
serum
associ
fatal
outcom
piv
infect
lower
respiratori
tract
diseas
immunosuppress
patient
particularli
immedi
posttransplant
period
may
result
similar
clinic
pictur
although
overal
mortal
rate
may
less
associ
rsv
mani
immunocompromis
adult
piv
infect
first
present
symptom
mild
upper
respiratori
tract
diseas
contrast
rsv
influenza
hmpv
detect
asymptomat
hct
recipi
rel
common
report
infect
episod
prospect
studi
fewer
half
pivinfect
patient
fever
sever
immunocompromis
patient
allogen
hct
recipi
less
day
transplant
common
piv
subtyp
detect
report
hct
recipi
piv
pivinfect
transplant
recipi
infect
may
progress
lower
respiratori
tract
diseas
seriou
diseas
link
supplement
oxygen
requir
low
monocyt
count
highdos
steroid
use
detect
piv
bal
lower
respiratori
tract
specimen
associ
decreas
surviv
overal
hct
recipi
higher
pretranspl
antibodi
level
protect
sever
sequela
concomit
infect
virus
fungi
sever
graftversushost
diseas
rel
common
adult
patient
piv
pneumon
influenza
remain
signific
caus
morbid
mortal
immunocompromis
children
adult
recent
multicent
review
immunocompromis
children
hospit
influenza
immunocompromis
children
like
present
fever
less
like
present
respiratori
distress
also
less
like
requir
intens
care
hospit
longer
studi
adult
pediatr
hct
sot
recipi
subject
present
pneumonia
hospit
prior
vaccin
associ
decreas
diseas
sever
mortal
influenza
adult
pediatr
patient
studi
although
higher
mortal
rate
previous
report
increas
use
molecular
diagnost
assay
hrv
hcov
common
respiratori
virus
detect
immunocompromis
patient
hrv
detect
hct
recipi
progress
lower
respiratori
tract
infect
occur
patient
hrv
progress
mortal
rate
similar
respiratori
virus
includ
influenza
piv
rsv
addit
hrv
member
enteroviru
genu
includ
associ
outbreak
sever
diseas
enteroviru
associ
sever
hundr
case
sever
respiratori
ill
children
unit
state
sever
diseas
also
seen
immunocompromis
patient
hcov
also
associ
sever
diseas
lower
respiratori
tract
result
death
specif
consider
hct
sot
oncolog
patient
outlin
follow
text
hct
recipi
age
may
fulmin
cours
respiratori
viral
infect
particularli
infect
occur
around
time
transplant
risk
factor
diseas
progress
includ
lack
engraft
decreas
lymphocyt
count
older
age
evid
pulmonari
infiltr
chest
radiograph
may
delay
absent
patient
sever
neutropenia
may
becom
appar
immun
reconstitut
chest
comput
tomographi
magnet
reson
imag
multicent
retrospect
review
pediatr
hct
recipi
allcaus
attribut
casefat
rate
within
month
hospit
respiratori
viral
infect
onset
respect
lower
respiratori
tract
infect
rare
except
hmpv
infect
fever
common
influenza
hmpv
multivari
model
indic
onset
within
day
hct
steroid
use
day
onset
need
respiratori
support
onset
associ
subsequ
morbid
death
sever
risk
score
propos
adult
hct
recipi
respiratori
viru
infect
predict
risk
progress
lower
respiratori
tract
infect
mortal
sot
recipi
larg
multicent
retrospect
review
fever
common
clinic
sign
detect
although
signific
proport
sign
lower
respiratori
tract
infect
onset
detect
respiratori
viral
infect
sot
recipi
associ
allcaus
attribut
casefat
rate
respect
receipt
abdominalintestin
multiviscer
transplant
associ
increas
risk
allcaus
death
multivari
model
overal
approxim
patient
respiratori
viral
infect
requir
form
respiratori
support
oncolog
patient
adult
leukemia
profound
chemotherapyinduc
myelosuppress
also
risk
fatal
outcom
respiratori
virus
pediatr
patient
fever
neutropenia
episod
caus
differ
type
respiratori
virus
differ
clinic
outcom
day
hospit
day
fever
oxygen
requir
admiss
intens
care
unit
death
compar
patient
singl
viru
versu
coinfect
mainstay
influenza
prevent
immunocompromis
children
vaccin
inactiv
influenza
vaccin
iiv
recommend
patient
month
older
hematolog
malign
infecti
diseas
societi
america
idsa
guidelin
vaccin
recommend
patient
receiv
intens
chemotherapi
induct
consolid
chemotherapi
acut
leukemia
receiv
antibcel
antibodi
past
month
live
attenu
influenza
vaccin
laiv
use
immunosuppress
patient
except
outbreak
set
laiv
determin
effect
option
owe
strain
type
quadrival
vaccin
offer
avail
studi
ongo
assess
immunogen
safeti
highdos
influenza
vaccin
immunocompromis
adult
children
influenza
vaccin
recommend
famili
member
close
contact
health
care
worker
care
immunocompromis
patient
laiv
recommend
household
contact
hct
recipi
within
month
transplant
sever
immunosuppress
result
graftversushost
diseas
sever
combin
immun
defici
laiv
given
person
care
sever
immunosuppress
patient
center
diseas
control
prevent
guidelin
recommend
avoid
contact
day
vaccin
hct
recipi
immun
respons
influenza
vaccin
like
effect
hct
hct
recipi
month
older
receiv
iiv
annual
start
month
transplant
start
month
transplant
commun
outbreak
influenza
second
dose
recommend
children
depend
time
transplant
reduc
intens
hct
pretranspl
vaccin
may
appropri
host
immun
expect
extend
earli
transplant
period
highdos
vaccin
current
studi
pediatr
adult
hct
recipi
sot
recipi
idsa
guidelin
recommend
administ
influenza
vaccin
intensifi
immunosuppress
includ
first
posttranspl
period
likelihood
inadequ
respons
howev
commun
outbreak
iiv
administ
month
later
transplant
earlier
vaccin
support
recent
studi
data
regard
highdos
vaccin
repeat
vaccin
dose
within
season
also
becom
avail
oncolog
patient
iiv
recommend
patient
older
postexposur
chemoprophylaxi
consid
immunosuppress
patient
close
contact
confirm
influenza
case
influenza
outbreak
outbreak
set
hct
recipi
receiv
vaccin
immedi
month
longer
posttranspl
chemoprophylaxi
oseltamivir
zanamivir
also
initi
week
vaccin
immun
develop
chemoprophylaxi
also
recommend
hct
recipi
less
month
posttranspl
remain
substanti
immunocompromis
month
longer
hct
regardless
vaccin
histori
sot
similar
concern
regard
vaccin
respons
earli
posttranspl
period
exist
chemoprophylaxi
consid
although
recommend
regard
time
strategi
lack
seasonlong
prophylaxi
evalu
random
trial
sot
hct
show
reduct
cultureor
polymeras
chain
reaction
pcr
confirm
influenza
although
approach
univers
use
may
target
period
high
influenza
viru
circul
antivir
resist
may
emerg
widespread
prophylaxi
drug
resist
pattern
circul
strain
consid
initi
prophylaxi
andor
preemptiv
therapi
new
advanc
understand
rsv
hmpv
includ
character
rsv
fusion
f
protein
preinfus
postfus
state
contribut
develop
new
rsv
vaccin
monoclon
antibodi
potenti
use
prophylaxi
rsv
vaccin
stimul
antibodi
direct
f
protein
specif
pref
protein
develop
rsvspecif
serumneutr
antibodi
effici
transfer
mother
newborn
ongo
clinic
trial
may
offer
potenti
protect
rsv
famili
member
health
care
worker
surround
immunocompromis
patient
potenti
protect
patient
candid
vaccin
piv
hmpv
well
chimer
vaccin
contain
gene
one
viru
also
test
preclin
model
identif
serumneutr
antibodi
correl
protect
seriou
rsv
lower
respiratori
tract
diseas
import
advanc
although
human
monoclon
antibodi
direct
rsv
f
protein
palivizumab
licens
sinc
prevent
rsv
diseas
young
children
underli
cardiac
pulmonari
diseas
also
current
use
children
sever
immunocompromis
infant
sever
combin
immun
defici
congenit
leukemia
children
younger
month
profoundli
immunocompromis
may
consid
palivizumab
prophylaxi
develop
potent
longact
rsv
monoclon
antibodi
direct
pref
protein
rsv
undergo
clinic
trial
young
infant
similar
product
may
avail
futur
prevent
rsv
infect
diseas
transplant
candid
passiv
immunoprophylaxi
piv
hmpv
infect
studi
children
diagnosi
respiratori
viral
infect
critic
depend
type
qualiti
clinic
specimen
proper
handl
specimen
prefer
specimen
diagnosi
respiratori
virus
immunocompromis
host
respiratori
secret
obtain
midturbin
nasopharyng
swab
nasal
wash
nasal
aspir
bronchoalveolar
lavag
nasal
wash
specimen
classic
sampl
use
viral
diagnosi
cultur
obtain
sampl
assess
cytokin
antibodi
nasopharyng
swab
midturbin
swab
sensit
nasal
wash
viral
diagnosi
use
cultur
good
diagnost
yield
molecular
detect
method
gener
molecular
method
detect
prefer
fluoresc
antigenantibodi
detect
antigen
detect
test
immunocompromis
patient
specimen
children
often
readili
diagnos
adult
owe
higher
viral
load
clinic
specimen
use
detect
respiratori
virus
patient
age
includ
endotrach
aspir
collect
intub
patient
bronchoalveolar
lavag
nasal
mucos
epithelium
collect
scrape
sputum
lung
tissu
obtain
biopsi
autopsi
molecular
diagnost
multiplex
realtim
pcr
replac
cell
cultur
fluoresc
antigenantibodi
detect
antigen
detect
methodolog
high
sensit
specif
excel
qualiti
control
procedur
detect
larg
batteri
viral
bacteri
pathogen
rapidli
singl
sampl
use
molecular
diagnost
significantli
improv
yield
detect
numer
rapid
multiplex
pcr
assay
commerci
avail
detect
virus
simultan
assay
sensit
specif
detect
rsv
hmpv
influenza
hrv
hcov
differenti
four
piv
subtyp
potenti
hypoxemia
apnea
poor
oral
intak
result
infect
young
infant
previous
healthi
well
moder
sever
immunocompromis
requir
close
medic
manag
hospit
may
requir
immunocompromis
children
younger
year
particularli
intraven
iv
fluid
replac
oxygen
therapi
necessari
system
inhal
steroid
bronchodil
therapi
recommend
treatment
rsv
base
studi
fail
show
decreas
time
hospit
improv
outcom
children
airway
obstruct
sign
hypoxia
requir
admiss
intens
care
set
close
monitor
children
sever
diseas
may
requir
intub
support
care
lower
respiratori
tract
infect
caus
piv
hmpv
immunocompromis
host
similarli
may
requir
hospit
adjunct
therapi
includ
iv
fluid
oxygen
support
well
aggress
therapi
secondari
fungal
bacteri
viral
infect
respiratori
syncyti
viru
ribavirin
synthet
guanosin
nucleosid
licens
treatment
rsv
respiratori
diseas
children
sinc
treatment
rsv
diseas
patient
undergo
mechan
ventil
sinc
ribavirin
approv
drug
lower
respiratori
tract
diseas
caus
rsv
concern
regard
efficaci
difficulti
administr
extrem
high
cost
drug
result
minim
current
use
drug
ribavirin
avail
aerosol
oral
iv
form
sever
retrospect
studi
includ
pool
analysi
shown
aerosol
oral
ribavirin
protect
diseas
progress
lower
respiratori
tract
infect
mortal
hct
recipi
howev
conclus
evid
efficaci
random
trial
avail
patient
leukemia
multivari
model
demonstr
similar
effect
oral
ribavirin
retrospect
evalu
patient
receiv
chemotherapi
hct
recipi
suggest
possibl
effect
oral
ribavirin
howev
lack
random
control
limit
studi
adult
hct
hematolog
malign
patient
rsv
lower
respiratori
tract
infect
use
aerosol
ribavirin
associ
decreas
mortal
oral
iv
ribavirin
although
statist
signific
effect
smaller
note
data
suggest
pediatr
hct
recipi
rsv
littl
morbid
mortal
even
without
ribavirin
therapi
current
intern
guidelin
recommend
aerosol
system
oral
iv
ribavirin
intraven
immunoglogulin
ivig
patient
rsv
upper
respiratori
tract
infect
undergo
allogen
hct
allogen
hct
recipi
risk
factor
progress
lower
respiratori
tract
infect
allogen
hct
patient
lower
respiratori
tract
infect
recommend
ribavirin
administr
hct
sot
recipi
oncolog
patient
outlin
tabl
data
guidanc
use
ribavirin
hct
oncolog
studi
clearli
demonstr
efficaci
sot
recipi
data
lung
transplant
oral
iv
ribavirin
use
hct
oncolog
patient
highrisk
situat
includ
patient
lymphopenia
addit
risk
factor
smoke
histori
use
highdos
total
bodi
irradi
could
use
riskstratifi
patient
gener
aerosol
ribavirin
reserv
subject
virolog
confirm
bal
posit
rsv
lower
respiratori
tract
infect
administ
smallparticl
aerosol
solut
contain
drug
concentr
mgml
steril
water
via
aerosol
hoursday
concentr
mgml
water
hour
time
daili
aerosol
administr
result
high
level
ribavirin
secret
level
exceed
mm
littl
system
absorpt
potenti
environment
releas
ribavirin
caus
concern
hospit
personnel
potenti
teratogen
ribavirin
thu
exposur
contraind
pregnant
women
teratogen
potenti
administr
ribavirin
via
ventil
use
highdos
shortdur
method
drug
deliveri
vacuumexhaust
treatment
hood
result
minim
detect
ribavirin
room
treat
children
oral
ribavirin
consid
patient
weigh
hemolyt
anemia
import
side
effect
consid
patient
monitor
care
system
antibodi
therapi
combin
antibodi
therapi
ribavirin
aerosol
antibodi
use
treat
rsv
diseas
combin
hightit
rsv
immunoglobulin
ribavirin
associ
therapeut
success
uncontrol
studi
sever
immunocompromis
adult
rsv
diseas
confirm
other
small
nonrandom
unadjust
analysi
pediatr
cancer
patient
rsv
lower
respiratori
tract
infect
suggest
benefici
effect
adjunct
palivizumab
ivig
larger
studi
hct
recipi
rsv
lower
respiratori
tract
infect
unabl
demonstr
improv
outcom
adjunct
palivizumab
palivizumab
current
recommend
treatment
rsv
infect
immunocompromis
patient
durat
ribavirin
therapi
immunocompromis
host
gener
least
day
initi
antivir
therapi
stage
upper
respiratori
tract
diseas
may
decreas
viral
load
possibl
reduc
risk
respiratori
failur
although
data
base
retrospect
uncontrol
data
earli
influenza
treatment
recommend
immunocompromis
individu
although
may
benefit
even
delay
treatment
inhibitor
amantadin
rimantadin
current
ineffect
neuraminidas
inhibitor
nai
firstlin
therapi
prophylaxi
treatment
influenza
nai
avail
unit
state
includ
oral
oseltamivir
inhal
zanamivir
iv
peramivir
baloxavir
clinic
efficaci
oseltamivir
inhal
zanamivir
demonstr
patient
leukemia
hct
recipi
mani
mutat
caus
oseltamivir
peramivir
resist
includ
common
mutat
influenza
confer
resist
zanamivir
inhal
zanamivir
may
use
treat
strain
iv
peramivir
use
pandem
sever
ill
patient
well
toler
evid
recoveri
patient
random
trial
compar
iv
peramivir
oral
oseltamivir
hospit
adult
clinic
outcom
similar
optim
durat
peramivir
therapi
determin
immunocompromis
host
longer
treatment
cours
day
although
higher
dose
oseltamivir
zanamivir
suggest
given
potenti
recurr
median
time
progress
lower
respiratori
tract
infect
baloxavir
recent
approv
treatment
uncompl
influenza
adult
adolesc
studi
younger
children
immunocompromis
host
underway
multidrugresist
influenza
strain
identifi
immunocompromis
patient
triplecombin
antivir
therapi
amantadin
ribavirin
oseltamivir
propos
treat
immunocompromis
patient
sever
influenza
resist
oseltamivir
random
trial
compar
triplecombin
antivir
therapi
oseltamivir
alon
highrisk
adult
demonstr
effect
viral
outcom
clinic
benefit
parainfluenza
retrospect
studi
patient
leukemia
hct
recipi
piv
infect
ribavirin
impact
viral
shed
symptom
hospit
length
progress
lower
respiratori
tract
infect
mortal
systemat
review
evalu
aerosol
system
ribavirin
retrospect
studi
popul
found
differ
pivassoci
mortal
progress
lower
respiratori
tract
infect
given
lack
evid
clinic
efficaci
ribavirin
recommend
piv
infect
impact
ivig
alon
remain
determin
although
ivig
administr
piv
lower
respiratori
tract
infect
reduc
mortal
respiratori
virus
manag
respiratori
viral
infect
immunosuppress
patient
gener
support
tabl
ribavirin
shown
efficaci
hmpv
vitro
mous
model
anecdot
report
describ
use
sever
infect
immunocompromis
host
without
ivig
lack
control
studi
ribavirin
known
toxic
therapi
includ
hemolyt
anemia
limit
recommend
hmpv
current
approv
antivir
agent
exist
treatment
hcov
hrv
hbov
enterovirus
although
investig
agent
upcom
use
ivig
evalu
prospect
routin
recommend
treatment
respiratori
viral
infect
center
routin
check
replet
immunoglobulin
impact
respiratori
viru
acquisit
sever
known
new
rsv
antivir
candid
investig
includ
presatovir
gilead
scienc
foster
citi
ca
oral
rsv
fusion
inhibitor
lumicitabin
aliosjanssen
titusvil
nj
rsv
nucleosid
analog
act
rsv
viral
polymeras
antivir
test
human
challeng
model
success
demonstr
antivir
efficaci
presatovir
subsequ
underw
two
larg
placebocontrol
clinic
efficaci
trial
treatment
rsv
placebocontrol
studi
conduct
adult
hsct
patient
upper
lower
respiratori
tract
infect
respect
clinic
trial
endpoint
efficaci
met
presatovir
studi
lumicitabin
also
suspend
new
studi
anoth
nucleosid
analog
janssen
underway
young
children
nanobodi
small
antibodylik
molecul
deriv
heavychain
variabl
ig
domain
occur
natur
camel
develop
administ
inhal
treatment
rsv
infect
ablynx
nv
ghent
belgium
vaccin
rsv
piv
develop
discuss
earlier
new
potenti
antivir
therapi
piv
sialic
acidbind
virus
target
lung
epitheli
sialic
acid
receptor
piv
therebi
prevent
viral
entri
novel
recombin
sialidas
fusion
protein
ansun
biopharma
san
diego
ca
first
develop
antivir
agent
influenza
function
cleav
sialic
acid
host
cell
surfac
therebi
inactiv
host
cell
receptor
recogn
piv
success
use
agent
pediatr
adult
transplant
recipi
compassion
use
report
clinic
trial
immunocompromis
subject
ongo
sever
studi
novel
influenza
therapeut
investig
includ
nai
iv
zanamivir
laninamivir
monoclon
antibodi
viral
polymeras
inhibitor
nitazoxanid
perform
safeti
newer
agent
remain
seen
immunocompromis
children
rsv
piv
hmpv
common
caus
nosocomi
infect
contribut
signific
morbid
mortal
pediatr
ward
nosocomi
rsv
piv
infect
adult
leukemia
bone
marrow
transplant
associ
high
mortal
rate
transmiss
ident
strain
rsv
outpati
set
hospit
document
demonstr
import
infect
control
measur
nosocomi
transmiss
hmpv
also
occur
outbreak
inpati
outpati
unit
one
studi
patient
diagnos
hmpv
within
week
tertiari
care
cancer
unit
molecular
subtyp
reveal
infect
genotyp
viru
implic
nosocomi
transmiss
four
patient
die
hmpvassoci
pneumonia
consequ
multiorgan
failur
nosocomi
outbreak
characterist
occur
multipl
introduct
commun
respiratori
viral
strain
well
patienttopati
spread
perhap
health
care
provid
intermediari
prevent
nosocomi
transmiss
contact
isol
precaut
effect
provid
complianc
polici
maintain
among
personnel
hospit
personnel
may
play
role
transmiss
rsv
respiratori
virus
suscept
patient
viral
spread
limit
adher
strict
handwash
procedur
cohort
infect
expos
individu
use
glove
mask
goggl
hospit
set
also
limit
spread
strict
measur
appropri
highrisk
set
pediatr
intens
care
unit
bone
marrow
transplant
ward
restrict
visitor
includ
young
children
hospit
ward
patient
high
risk
rsv
infect
may
necessari
epidem
period
commun
continu
complianc
respiratori
viru
season
member
health
care
team
critic
import
isol
base
symptom
oppos
posit
viral
test
result
shown
prolong
shed
respiratori
virus
even
minim
symptom
may
complic
effort
infect
control
patient
known
suspect
infect
influenza
rsv
piv
hmpv
kept
contact
isol
cohort
symptom
resolv
repeat
sensit
diagnost
test
result
neg
piv
outbreak
may
difficult
bring
control
owe
prolong
asymptomat
shed
particularli
young
children
immunocompromis
host
intern
guidelin
recommend
deferr
condit
therapi
patient
respiratori
infect
prior
allogen
hct
low
strength
evid
concern
progress
ill
respiratori
viral
infect
need
balanc
concern
underli
diseas
progress
donor
avail
larg
prospect
studi
respiratori
virus
detect
hct
patient
transplant
viral
detect
associ
prolong
hospit
lower
surviv
day
risk
also
present
patient
hrv
alon
recent
retrospect
review
hrv
detect
pediatr
hct
recipi
demonstr
hrv
detect
without
presenc
lower
respiratori
tract
infect
associ
decreas
day
aliv
hospit
suggest
hct
delay
alway
warrant
data
ideal
valid
larger
multicent
studi
impact
factor
viralspecif
risk
score
locat
infect
viral
load
need
evalu
pediatr
patient
diagnost
pcr
consid
transplant
candid
regardless
symptom
transplant
delay
consid
feasibl
ongo
symptom
evid
lower
respiratori
tract
infect
sot
candid
limit
data
examin
clinic
outcom
pretranspl
respiratori
viral
infect
often
organ
avail
signific
consider
proceed
transplant
specif
clinic
circumst
durat
infect
sever
symptom
consid
donor
transmiss
influenza
particular
concern
lung
small
bowel
transplant
howev
nonlung
nonsmal
bowel
organ
consid
donor
antivir
treatment
hour
coupl
treatment
recipi
clear
guidanc
exist
respiratori
virus
decis
regard
organ
use
infect
donor
evalu
casebycas
basi
keyword
hematopoiet
cell
transplant
immunocompromis
oncolog
respiratori
viru
solid
organ
transplant
viral
pneumonia
abstract
respiratori
virus
commonli
detect
healthi
immunocompromis
children
healthi
children
respiratori
virus
associ
selflimit
upper
respiratori
tract
infect
accompani
signific
morbid
immunocompromis
host
includ
hematopoiet
cell
transplant
recipi
solid
organ
transplant
recipi
oncolog
patient
respiratori
virus
associ
signific
clinic
manifest
includ
prolong
viral
shed
lower
respiratori
tract
diseas
need
supplement
oxygen
late
airflow
obstruct
even
death
chapter
review
major
respiratori
virus
includ
respiratori
syncyti
viru
human
metapneumoviru
influenza
parainfluenza
virus
human
rhinovirus
human
coronavirus
virus
manifest
pulmonari
infect
howev
virus
discuss
elsewher
see
chapter
discuss
cytomegaloviru
chapter
discuss
adenovirus
